高危心力衰竭患者同时接种流感疫苗与呼吸道合胞病毒(RSV)疫苗的早期安全性特征
该开放标签前瞻性研究纳入105例高危心力衰竭患者,于2023年9月15日至11月17日同时接种流感疫苗(Vaxigrip Tetra,2023/2024季,赛诺菲)和RSV疫苗(Arexvy,葛兰素史克),接种后第4天收集不良事件。总体耐受良好,最常见为注射部位疼痛(63%),全身症状33%,3级反应6%,接种后一周内无心力衰竭加重、住院或死亡。
要点
- 高危心衰患者同时接种流感与RSV疫苗总体耐受良好,最常见为注射部位疼痛(63%)。
- 全身症状发生于33%患者,主要为疲乏(23%)、肌痛(12%)和头痛(9%)。
- 3级反应见于6%患者,接种后一周内无心力衰竭加重、住院或死亡。
核心结论
- 在高危心力衰竭患者中同时接种流感疫苗与RSV疫苗具有安全性,轻度不良事件发生率低。
研究设计与样本
- 开放标签前瞻性研究,纳入105例高危心力衰竭患者,于2023年9月15日至11月17日同时接种流感疫苗(Vaxigrip Tetra,2023/2024季,赛诺菲)和RSV疫苗(Arexvy,葛兰素史克),接种后第4天收集不良事件。
主要发现
- 总体耐受良好,最常见反应为注射部位疼痛(63%)。
- 全身症状发生于33%患者,主要为疲乏(23%)、肌痛(12%)和头痛(9%)。
- 3级反应见于6%患者,少数出现体温升高或流感样症状,使用退热药处理。
- 接种后一周内无心力衰竭加重、住院或死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The safety of simultaneous vaccination for Respiratory Syncytial Virus (RSV) and influenza in vulnerable high-risk heart failure (HF) patients remains unclear. In an open-label, prospective study, 105 patients received concurrent influenza (Vaxigrip Tetra, season 2023/2024, Sanofi) and RSV (Arexvy, GSK) vaccinations from September 15th to November 17th, 2023. Adverse events were collected on the fourth-day post-vaccination. Overall, the vaccination was well tolerated, with the most common reaction being injection site pain (63 %). General symptoms occurred in 33 % of patients, predominantly fatigue (23 %), myalgia (12 %), and headache (9 %). Grade 3 reactions were observed in 6 % of patients, and a few experienced temperature elevation or flu-like symptoms, managing them with antipyretics. Notably, there were no exacerbations of HF, hospitalizations, or deaths within a week post-vaccination. This study indicates the safety of simultaneous influenza and RSV vaccination in high-risk HF patients, with a low incidence of mild adverse events.
引用
- Biegus J, Szenborn L, Zymliński R, et al. The early safety profile of simultaneous vaccination against influenza and Respiratory Syncytial Virus (RSV) in patients with high-risk heart failure. Vaccine. 2024. PMID: 38531725. doi:10.1016/j.vaccine.2024.03.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。